Asset sale Announced

Harrow acquisition of TYRVAYA (varenicline solution) nasal spray 0.03 mg

US$30m consideration

Announced 6 Aug 2026

Advisers

TYRVAYA (varenicline solution) nasal spray 0.03 mg

Target

Harrow

Acquirer

Not disclosed

Target
TYRVAYA (varenicline solution) nasal spray 0.03 mg
Acquirer
Harrow
Seller
Viatris
Target based in
United States (unverified)
Buyer based in
United States
Seller based in
United States
Sector
Pharma
Tags
Pharma, Ophthalmology

In the league tables

Similar deals

All pharma deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.